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Original Article

Six-Year Follow-up of a Trial of Antenatal
Vitamin D for Asthma Reduction
Augusto A. Litonjua, M.D., M.P.H., Vincent J. Carey, Ph.D.,
Nancy Laranjo, B.A., Benjamin J. Stubbs, B.A., Hooman Mirzakhani, M.D., Ph.D.,
George T. O’Connor, M.D., Megan Sandel, M.D., M.P.H., Avraham Beigelman, M.D.,
Leonard B. Bacharier, M.D., Robert S. Zeiger, M.D., Ph.D., Michael Schatz, M.D.,
Bruce W. Hollis, Ph.D., and Scott T. Weiss, M.D.

A BS T R AC T
BACKGROUND

We previously reported the results of a trial of prenatal vitamin D supplementation
to prevent asthma and recurrent wheeze in young children, which suggested that
supplementation provided a protective effect at the age of 3 years. We followed the
children through the age of 6 years to determine the course of asthma and recurrent wheeze.
METHODS

In this follow-up study, investigators and participants remained unaware of the
treatment assignments through the children’s sixth birthday. We aimed to determine whether, when maternal levels of 25-hydroxyvitamin D were taken into account, children born to mothers who had received 4400 IU of vitamin D3 per day
during pregnancy (vitamin D group) would have a lower incidence of asthma and
recurrent wheeze at the age of 6 years than would those born to mothers who had
received 400 IU of vitamin D3 per day (control group). Time-to-event methods were
used to compare the treatment groups with respect to time to the onset of asthma
or recurrent wheeze. Multivariate methods were used to compare longitudinal
measures of lung function between the treatment groups.
RESULTS

There was no effect of maternal vitamin D supplementation on asthma and recurrent wheeze in either an intention-to-treat analysis or an analysis with stratification according to the maternal 25-hydroxyvitamin D level during pregnancy. There
was no effect of prenatal vitamin D supplementation on most of the prespecified
secondary outcomes. We found no effects of prenatal supplementation on spirometric indexes. Although there was a very small effect on airway resistance as
measured by impulse oscillometry, this finding was of uncertain significance.
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CONCLUSIONS

Vitamin D supplementation during the prenatal period alone did not influence the
6-year incidence of asthma and recurrent wheeze among children who were at risk
for asthma. (Funded by the National Heart, Lung, and Blood Institute; VDAART
ClinicalTrials.gov number, NCT00920621.)
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itamin D deficiency has been hypothesized to have contributed to the increase in asthma and allergies in westernized societies.1 Because asthma and wheezing
illnesses begin very early in life, studies of prenatal and early-life risk factors are crucial. Observational studies have suggested that a higher
maternal vitamin D level is associated with a
lower risk of asthma-related outcomes among
children, and clinical trials with adequate dosing of vitamin D, therefore, are needed to investigate whether prenatal vitamin D supplementation could prevent the development of asthma.
We conducted the Vitamin D Antenatal Asthma Reduction Trial (VDAART), a trial of prenatal vitamin D supplementation to prevent asthma
and wheeze in young children through their third
birthday.2 We previously reported our results,
which suggested a reduction in asthma and recurrent wheeze in 3-year-old children in association with vitamin D supplementation.3 Secondary
analyses showed that the effect of supplementation was significantly stronger among children
born to mothers who had higher vitamin D levels
at entry into the trial in early pregnancy,4 which
suggested that maternal levels are important
considerations. A meta-analysis of data from our
trial and another trial of prenatal vitamin D
supplementation showed a significant protective
effect of prenatal supplementation on asthma
and recurrent wheeze at 3 years5 and confirmed
that the effect was strongest in women with an
initial 25-hydroxyvitamin D level of at least 30
ng per milliliter (75 nmol per liter).
Since asthma in early life is difficult to ascertain with confidence and early wheezing is probably a conglomerate of different phenotypes, we
continued to follow the children in our previously
reported clinical trial through their sixth birthday. In this report, we present the results of our
follow-up study, in which we examined whether
prenatal supplementation with 4400 IU of vitamin D3 or 400 IU of vitamin D3 per day, with
maternal levels of 25-hydroxyvitamin D taken into
account, would lead to a decreased incidence of
asthma and recurrent wheeze at the age of 6 years.

of
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St. Louis; and Kaiser Permanente Southern California Region, San Diego. The data coordinating
center was based in the Channing Division of
Network Medicine, Brigham and Women’s Hospital, Boston. Eligible participants were women
between the ages of 18 and 39 years who presented when the estimated duration of the ongoing pregnancy was between 10 and 18 weeks;
who had a history of asthma, eczema, or allergic
rhinitis or whose partner (biologic father of the
child) had a history of asthma, eczema, or allergic rhinitis; who was a nonsmoker; and who was
English- or Spanish-speaking and intended to
participate for 4 years (up to the third birthday
of the child). The purpose of this follow-up
study was to determine whether the early findings concerning the effect of vitamin D supplementation would extend to the sixth birthday of
the child.
The original VDAART trial protocol and the
protocol for the follow-up study, available with
the full text of this article at NEJM.org, were approved by the institutional review boards at each
participating institution. All women provided
written informed consent. The authors vouch for
the accuracy and completeness of the data and
for the fidelity of the study to the protocol.
Trial Design

Details of the trial design and protocol through
the age of 3 years have been published previously.2,3 VDAART was a randomized, double-blind,
placebo-controlled trial of prenatal vitamin D
supplementation in which participants received
either a daily vitamin D dose of 4000 IU plus a
multivitamin with 400 IU of vitamin D (vitamin D
group) or daily placebo plus a multivitamin with
400 IU of vitamin D (control group). Participants
were screened for eligibility from October 2009
through July 2011. The original research grant
that funded the trial was a cooperative agreement with the National Heart, Lung, and Blood
Institute (NHLBI) of the National Institutes of
Health that lasted for 5 years, and the outcomes
were ascertained when the children were 3 years
old.3 Because of the heterogeneity in the earlylife asthma and wheeze phenotype, the intention
was to renew the grant to enable follow-up
Me thods
through the children’s sixth birthday and thereParticipants
by analyze a more definitive phenotype.
We recruited pregnant women from three clinical
The current study followed the children from
sites across the United States — Boston Medical their third birthday through their sixth birthday.
Center, Boston; Washington University at St. Louis, Follow-up of the last child was completed in
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January 2018. Prenatal interval visits, labor and
delivery room data collection, and postnatal visits and data collected during these visits have
been detailed previously.2,3 The participants and
investigators remained unaware of the treatmentgroup assignments until after the visit corresponding to each child’s sixth birthday.
The primary outcome for this follow-up study
was an extension of that in the original analysis
— asthma, recurrent wheeze, or both. Asthma
was defined as a maternal or caregiver report of
physician-diagnosed asthma, and time of onset
was defined as the first report of wheezing or
the first report of the use of any asthma medication (see the Supplementary Appendix, available
at NEJM.org). Recurrent wheeze was defined as
maternal or caregiver report of wheeze or the
use of any asthma medication in 2 separate
years over the first 6 years, and the time of onset
was the first report of wheeze or the first report
of the use of any asthma medication. Analyses of
lung-function measures involved data from children who had completed at least two acceptable
spirometry or impulse oscillometry tests and
whose mother provided vitamin D results at baseline or during the third trimester.
We prespecified several secondary outcomes,
including active asthma, parental report of physician’s diagnosis of eczema, parental report of
physician’s diagnosis of allergic rhinitis, total
IgE levels, allergen sensitization (specific IgE to
a panel of aeroallergens and food allergens),
lower respiratory tract infections, and lungfunction measures. Details of the definitions of
these outcomes are provided in the Supplementary Appendix.
Lung function was measured by impulse oscillometry at 4 years of age and yearly after that.
Spirometry was performed at the 5- and 6-year
visits. Impulse oscillometry and spirometry were
performed with the MasterScreen IOS and MasterScreen PFT systems with the Jaeger pneumotach
(formerly CareFusion, now Vyaire Medical). Participants were instructed that the children
should refrain from using bronchodilator inhalers, syrups, or pills for at least 8 hours before
the visit and glucocorticoid inhalers or nebulizers
and leukotriene modifiers for 24 hours before
the visit. All impulse oscillometry and spirometry results were reviewed by expert reviewers
from the Pulmonary Function Laboratory of the
University of Wisconsin, Madison, who were unaware of the treatment assignments. Acceptabiln engl j med 382;6

ity and repeatability standards adhered to American Thoracic Society guidelines. For spirometry,
acceptability criteria were modified to allow for
a minimum expiratory time of 1 second, with
a 3-second expiratory time or a plateau in the
volume–time curve preferred for acceptability.
For analyses, we included tests with at least two
acceptable maneuvers.
Blood samples were obtained from mothers
at enrollment and at 32 to 38 weeks of gestation.
Cord blood was obtained at delivery, and children had blood samples obtained at the ages of
1, 3, and 6 years. Circulating 25-hydroxyvitamin D
levels from maternal and child plasma samples
were determined with the DiaSorin Liaison chemiluminescence immunoassay,6 whereas liquid
chromatography–tandem mass spectrometry7 was
used for cord-blood samples.
Statistical Analysis

We conducted two prespecified analyses to evaluate the effect of prenatal vitamin D supplementation on asthma risk in children. First, we tested
the null hypothesis that there was no treatment
effect on the risk of the development of physician-diagnosed asthma or recurrent wheeze by
age 6. This was an intention-to-treat analysis
of the primary outcome — that is, first onset of
asthma or recurrent wheeze. Second, to enhance
the risk model for asthma and recurrent wheeze
and the associated hypothesis test, we used
stratification according to mean maternal vitamin D concentration in pregnancy, including covariate adjustments. To maximize the use of
available information and to accommodate varying times between visits, nonparametric intervalcensored lifetime regression methods were used.8,9
For the intention-to-treat analysis, the estimated
hazard ratio comparing the low dose (control)
with the high dose is accompanied by a P value.
For the stratified secondary model, intervalcensored proportional-hazards regression was
used to compare event-free time distributions,
with adjustment for site, maternal asthma status, and the race and ethnic group of the child;
the hazard ratio and 95% confidence interval are
reported for the comparison of the bottom quartile with the top quartile of the mean maternal
vitamin D concentration.
For secondary categorical outcomes, differences in relative proportions are reported, and
for secondary continuous outcomes, mean differences are reported. No adjustments were made
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for multiple comparisons. For longitudinal measures of lung function, marginal means and
confidence intervals are reported for each treatment group, and linear mixed-effects modeling
was used to produce summarized group-specific,
covariate-adjusted estimates and confidence intervals.10

R e sult s
Participants

The flow of participants is shown in Figure 1,
and selected baseline characteristics of the participants are shown in Table 1 and in Table S1
in the Supplementary Appendix. A total of 806
children were included in the analysis. There
were no large differences in baseline characteristics. Acceptable lung-function measurements
were completed for a subpopulation of participants, and their characteristics are shown in
Table S2. The characteristics of the participants
in this subpopulation reflect the characteristics
of those in the overall trial population. The cordblood levels of 25-hydroxyvitamin D in children
born to mothers in the vitamin D group were
significantly higher than those in children born
to mothers in the control group, as was previously reported. Subsequent levels at the ages of
1, 3, and 6 years remained low and did not differ
significantly between the groups (Fig. S1).
Supplementation, Maternal
25-Hydroxyvitamin D Levels, and Childhood
Outcomes

By the age of 6 years, a total of 360 children
(44.7%) — 176 (43.5%) in the vitamin D group
and 184 (45.9%) in the control group — met the
criteria for the outcome of asthma or recurrent
wheeze. Of these 360 children, 198 (55.0%) had
a doctor’s diagnosis of asthma, and 344 (95.6%)
had recurrent wheezing.
There was no significant effect of maternal
supplementation with 4400 IU of vitamin D per
day on the incidence of asthma or recurrent
wheeze at the age of 6 years (184 events among
401 participants in the control group and 176
events among 405 participants in the vitamin D
group; interval-censored hazard ratio [control
vs. vitamin D], 1.12; P = 0.25) (Fig. 2). When
event times were stratified according to quartile
of mean prenatal level of vitamin D recorded in
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the mother’s serum, an effect was found, with a
higher risk among children born to mothers
with 25-hydroxyvitamin D levels of less than
20 ng per milliliter (50 nmol per liter) (Fig. S2).
An adjusted estimate of the hazard ratio among
children born to mothers in the top quartile of
mean prenatal 25-hydroxyvitamin D level (>35 ng
per milliliter; 76 events among 105 participants)
as compared with the bottom quartile (≤20 ng
per milliliter; 110 events among 200 participants)
was 0.74 (95% confidence interval [CI], 0.54
to 1.02).
There were no significant effects of maternal
vitamin D supplementation on the secondary
outcomes of eczema, allergic rhinitis, or lower
respiratory tract infection by 6 years of age (Table 2). Among children born to mothers in the
vitamin D group, the mean (±SD) log-transformed total IgE level was 3.91±1.64 log kU per
liter, and that among children born to mothers
in the control group was 4.22±1.70 log kU per
liter (mean difference, −0.31 log kU per liter;
95% CI, −0.64 to 0.01) (Table 2). Although the
number of children who were sensitized to any
allergen from the panel of 13 allergens did not
differ significantly between the groups, children
who were born to mothers in the vitamin D
group had fewer positive results of specific IgE
tests at 6 years of age than did children born to
mothers in the control group (Table 2).
The effects of prenatal supplementation on
childhood lung function were measured by impulse oscillometry and spirometry. In models
adjusted for race and ethnic group, clinical center, and sex of the child, total airway resistance
(resistance at 5 Hz [R5]) and lower peripheral
airway resistance (resistance at 5 Hz minus resistance at 20 Hz [R5 − R20]) were lower in the
vitamin D group than in the control group
among children 5 to 6 years of age (Table S3).
There was no association of prenatal vitamin D
supplementation with spirometric indexes.
Prenatal 25-Hydroxyvitamin D Levels
and Childhood Lung Function

Because baseline levels may affect the response
to supplementation, we investigated the effect of
maternal prenatal 25-hydroxyvitamin D levels on
the same lung-function measures. Among six
such secondary comparisons, we found that children born to mothers with mean 25-hydroxy
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9268 Women were assessed for eligibility

8387 Were excluded
1449 Were <18 yr or ≥40 yr of age
531 Did not speak English or Spanish
3317 Did not have atopy
1089 Declined to participate
160 Had moved or changed health care
provider
69 Were taking vitamin D supplements
of ≥2000 IU/day, unwilling to take
pills, or both
702 Were smokers or drug users
503 Had fetal anomaly, fetal demise,
or abortion
128 Were excluded for clinical reasons
30 Were incarcerated
389 Had multiple gestations or were
pregnant by IVF
20 Had other reason

881 Underwent randomization

439 Were assigned to receive 400 IU/day
vitamin D3 (control group)

442 Were assigned to receive 4400 IU/day
vitamin D3 (vitamin D group)
2 Were excluded
1 Had multiple gestations
1 Had a medical exclusion

3 Were excluded owing
to multiple gestations

440 Had singleton births
386 Had 25-hydroxyvitamin D levels
analyzed during third trimester
54 Had missing third-trimester sample
13 Had fetal or neonatal deaths
19 Could not be contacted or were
lost to follow-up
22 Did not have sample available

436 Had singleton births
391 Had 25-hydroxyvitamin D levels
analyzed during third trimester
45 Had missing third-trimester sample
13 Had fetal or neonatal deaths
18 Could not be contacted or were
lost to follow-up
14 Did not have sample available

35 Were excluded
15 Had fetal or neonatal
deaths
19 Could not be contacted
or were lost to follow-up
1 Was lost to follow-up
after delivery

35 Were excluded
14 Had fetal or neonatal
deaths
18 Could not be contacted
or were lost to follow-up
3 Were lost to follow-up
after delivery

405 Had children who were included
in the analysis of pediatric asthma
and recurrent wheeze
284 Had children who completed
impulse oscillometry or spirometry

401 Had children who were included
in the analysis of pediatric asthma
and recurrent wheeze
285 Had children who completed
impulse oscillometry or spirometry

Figure 1. Enrollment, Randomization, and Follow-up.
IVF denotes in vitro fertilization.

n engl j med 382;6

nejm.org

February 6, 2020

529

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on February 23, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

Table 1. Baseline Characteristics of the Participants.*
Vitamin D
(N = 405)

Control
(N = 401)

Overall
(N = 806)

Maternal age — yr

27.5±5.5

27.2±5.5

27.3±5.5

Gestational age at enrollment — wk

14.1±2.8

14.2±2.7

14.2±2.8

Characteristic

Gestational age at delivery — wk

39.0±1.9

39.0±2.0

39.0±1.9

Baseline maternal 25-hydroxyvitamin D level — ng/ml

23.3±10.3

22.6±10.2

23.0±10.2

History of asthma

171 (42.2)

151 (37.7)

322 (40.0)

History of hay fever

256 (63.2)

260 (64.8)

516 (64.0)

History of eczema

126 (31.1)

131 (32.7)

257 (31.9)

History of asthma

100 (24.7)

87 (21.7)

187 (23.2)

History of hay fever

164 (40.5)

180 (44.9)

344 (42.7)

History of eczema

77 (19.0)

56 (14.0)

133 (16.5)

200 (49.4)

220 (54.9)

420 (52.1)

175 (43.2)

172 (42.9)

347 (43.1)

Medical history of mother — no. (%)

Medical history of father — no. (%)

Male sex of child — no. (%)
Race and ethnic group of the child — no. (%)†
Black, Hispanic or non-Hispanic
White, Hispanic
White, non-Hispanic
Other

55 (13.6)

57 (14.2)

112 (13.9)

106 (26.2)

108 (26.9)

214 (26.6)

69 (17.0)

64 (16.0)

133 (16.5)

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. To convert the values for
25-hydroxyvitamin D to nanomoles per liter, multiply by 2.496.
†	Race and ethnic group were based on information reported by the mother about her own race and ethnic group and
about those of the biologic father.

vitamin D levels of less than 30 ng per milliliter
differed from those born to mothers with higher
25-hydroxyvitamin D levels in total airway resistance (adjusted mean R5, 1.01 kPa per liter per
second [95% CI, 0.99 to 1.03] vs. 0.96 kPa per
liter per second [95% CI, 0.93 to 0.99]) and peripheral airway resistance (adjusted mean R5−
R20, 0.35 kPa per liter per second [95% CI, 0.33
to 0.36] vs. 0.32 kPa per liter per second [95%
CI, 0.30 to 0.34]), forced expiratory volume in 1
second (FEV1) (adjusted mean, 0.97 liters [95%
CI, 0.94 to 0.99] vs. 1.00 liter [95% CI, 0.97 to
1.04]), and forced vital capacity (FVC) (adjusted
mean, 1.06 liters [95% CI, 1.04 to 1.09] vs. 1.12
liters [95% CI, 1.09 to 1.15]) (Fig. 3).

Discussion
Supplementation with vitamin D during the prenatal period alone did not prevent the development of asthma or recurrent wheeze in offspring
through the age of 6 years. Although a between530
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group difference was suggested at early time
points through the age of 3 years, this effect was
not sustained through the age of 6 years. Most of
the secondary analyses were also null, although
there was a small but uncertain effect of prenatal supplementation on total and peripheral airway resistance as measured by impulse oscillometry. Analyses according to mean prenatal
vitamin D level showed that higher levels were
associated with lower airway resistance and better spirometric lung-function indexes.
Vitamin D has pleiotropic effects in utero and
postnatally, particularly with respect to lung
development11 and immune function related to
asthma.12 Studies in murine models have established that vitamin D deficiency during pregnancy leads to alveolar simplification and impaired
airway development in offspring.13 Prenatal vitamin D supplementation abolishes most of the
detrimental lung effects in the offspring of vitamin D–deficient dams.14 A previously published
meta-analysis of our results and the results of a
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1.00

Probability of Being Event-free

Danish trial showed that prenatal supplementation had a significant effect in preventing asthma
or recurrent wheeze through the age of 3 years.5
However, our results and a recently published
follow-up study of the Danish trial15 show that
prenatal supplementation alone is not sufficient
to prevent childhood asthma through midchildhood.
Diagnosing asthma in early life is, at best,
difficult. Asthma in early childhood differs from
asthma in later childhood or adulthood.16 Assessments of wheezing phenotypes in several cohorts
have shown that some children may wheeze early
in life and not later, whereas others may have
either persistent wheeze or late-onset wheeze.17
Thus, children who wheeze in early childhood
may have remission of their symptoms by the
time they reach school age. Although there have
been attempts to predict which children with
early wheezing will go on to have asthma in
later life,17,18 none of these have proved to be very
accurate. This can be seen in our study, in which
only fair-to-moderate correspondence was found
between the children who had the outcome at
3 years and those who had the outcome at 6 years
(Cohen’s kappa, 0.51). It is possible that prenatal
vitamin D supplementation had an early effect
on only a minority of the wheezing phenotypes
in early childhood. Thus, these different phenotypes of early wheezing probably have different
causes, and combinations of different types of
interventions may be needed to more fully prevent the development of asthma by school age
and adolescence.

0.75

Vitamin D

Control

0.50

0.25

0.00

0

2

4

6

210
195

86
93

Years
No. at Risk
Vitamin D
Control

405
401

253
221

Figure 2. Intention-to-Treat Analysis of Asthma- and Wheeze-free Time
Distributions.
In the primary analysis, a nonparametric test accommodating interval
censored response times indicated that the betweengroup difference was
not significant (P = 0.25). Tick marks indicate censored data, and shading
around each line indicates the 95% confidence interval.

Viral infections are common in early childhood and cause many of the wheeze episodes in
this period of life. Given the actions of vitamin D
on antimicrobial peptides19,20 and virus-induced
inflammation,21 prenatal vitamin D supplementation may have prevented some of the specific
phenotypes of virus-induced wheezing in early
life.22 Since we did not collect nasal samples during wheezing episodes, we are unable to make
further statements regarding virus-induced wheeze

Table 2. Secondary Outcomes.
Outcome

Vitamin D

Control

Effect (95% CI)*

Active asthma — no./total no. (%)

74/361 (20.5)

59/346 (17.1)

3.5 (−2.5 to 9.5)

Recurrent wheeze without asthma diagnosis
— no./total no. (%)

40/361 (11.1)

55/346 (15.9)

−4.8 (−10.0 to 0.5)

Lateonset wheeze — no./total no. (%)

13/361 (3.6)

14/346 (4.0)

−0.4 (−3.6 to 4.0)

Eczema with typical rash — no./total no. (%)

96/361 (26.6)

91/346 (26.3)

0.2 (−6.4 to 7.1)

Allergic rhinitis — no./total no. (%)

131/361 (36.3)

143/346 (41.3)

−5.1 (−12.5 to 2.4)

Lower respiratory tract infection — no./total no. (%)

155/361 (42.9)

157/346 (45.4)

−2.4 (−10.0 to 5.1)

3.91±1.64

4.22±1.70

−0.31 (−0.64 to 0.01)

127/213 (59.6)

123/201 (61.2)

−1.6 (−11.0 to 8.0)

15

18

0.82 (0.71 to 0.95)

Total log IgE level — log kU/liter
Any allergic sensitization — no./total no. (%)
Percentage of 13 specific IgE tests with positive results

* For outcomes reported as numbers and percentages of participants, the effect is given as the percentagepoint difference
between the groups. For the percentage of positive results on specific IgE testing, the effect is given as the odds ratio.
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Figure 3. Lung-Function Measures Stratified According to Mean Maternal Vitamin D Level Status during Pregnancy.
Mixed-effects models for repeated lung-function outcome measures were adjusted for age, race, height, and weight.
Data points are mean values for each child from at least two successful oscillometry or spirometry tests. Boxes in
dicate the medians and interquartile ranges, and vertical lines indicate the 95% confidence intervals. FEV1 denotes
forced expiratory volume in 1 second, FVC forced vital capacity, and R5 resistance at 5 Hz (total airway resistance).

in our study. Another possible explanation for
the early wheeze prevention and the absence of
later wheeze and asthma prevention is that postnatal supplementation to maintain sufficient
vitamin D levels in children may be needed in
addition to the prenatal supplementation for
sustained effect.23,24 These issues will need to be
addressed in future studies.
In contrast to the findings of asthma and
recurrent wheeze, airway-resistance measures
obtained from impulse oscillometry were lower
among children born to mothers in the vitamin D
group than among children born to mothers in
the control group (Table S2). However, these effects were small and will need to be validated in
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future studies. No treatment effect was seen in
the traditional spirometric indexes of FEV1, FVC,
and the FEV1:FVC ratio.
Our trial has several limitations. First, because postnatal supplementation was not undertaken, we are unable to make any conclusions
about the combined effects of prenatal and postnatal supplementation on asthma and recurrent
wheeze. As suggested by the recently published
D-Wheeze study,23 postnatal supplementation has
effects in preventing recurrent wheeze. Furthermore, the differences in vitamin D levels noted
between the treatment groups in maternal and
cord blood were not sustained after birth, possibly contributing to the lack of effect by the age
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of 6 years. Next, women were enrolled in the
trial without regard to their initial vitamin D
level, and this is likely to have played a role in
biasing our results toward the null. Although
our previous secondary analyses suggested that
higher maternal levels early in pregnancy were
beneficial,4 a better-designed trial is needed. The
previously published results of our 3-year outcomes, in which the largest effect of supplementation was seen in the children born to the
mothers with higher vitamin D levels early in
pregnancy, may seem counterintuitive, since supplementation is thought to benefit those who
have a deficiency of the nutrient.25 However, since
human lung development starts at approximately 3 to 4 weeks of gestation,26 early vitamin D
levels may be important in this process.
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